KETOPROFEN

Details

Stereochemistry	RACEMIC
Molecular Formula	C16H14O3
Molecular Weight	254.2806
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C(O)=O)C1=CC(=CC=C1)C(=O)C2=CC=CC=C2

InChI

InChIKey=DKYWVDODHFEZIM-UHFFFAOYSA-N

InChI=1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)

HIDE SMILES / InChI

Molecular Formula	C16H14O3
Molecular Weight	254.2806
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21052564https://www.drugs.com/international/dexketoprofen.html
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT02159547 | https://www.ncbi.nlm.nih.gov/pubmed/28540716 | https://clinicaltrials.gov/ct2/show/NCT03122314 | https://www.ncbi.nlm.nih.gov/pubmed/28326850 | https://clinicaltrials.gov/ct2/show/NCT02092012

Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), manufactured by Menarini under the tradename Keral. Dexketoprofen is indicated for short-term treatment of mild to moderate pain, including dysmenorrhoea. Dexketoprofen works by blocking the action of a substance in the body called cyclo-oxygenase, which is involved in the production of chemicals in the body called prostaglandins. Prostaglandins are produced in response to injury or certain diseases and would otherwise go on to cause swelling, inflammation, and pain. By blocking cyclo-oxygenase, dexketoprofen prevents the production of prostaglandins and therefore reduces inflammation and pain. Along with peripheral analgesic action, it possesses central analgesic action. Dexketoprofen may cause dizziness, and patients should not, therefore, drive or operate heavy machinery or vehicles until they are familiar with how dexketoprofen affects them. Concomitant use of alcohol and other sedatives may potentiate this effect. In a small subset of individuals, the dizziness may be intolerable and require the transition to an alternative treatment.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Cyclooxygenase-1 131 Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10841807	Inhibitor 8504	1.9 nM [IC50]
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10841807	Inhibitor 8504	27.0 nM [IC50]
Interleukin-8 receptors, CXCR1/CXCR2 6 Target ID: CHEMBL2096909 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15974585	Antagonist 2849	50.0 nM [IC50]
Cyclooxygenase-2 201 Target ID: CHEMBL230 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14510637	Inhibitor 8504	0.52 µM [IC50]
Cyclooxygenase-1 131 Target ID: CHEMBL221 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14510637	Inhibitor 8504	0.019 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Pain, postoperative 9 Sources: https://clinicaltrials.gov/ct2/show/NCT02568735	Primary	Approved 8583	Keral Approved Use Unknown
Migraine 107 Sources: https://clinicaltrials.gov/ct2/show/NCT02159547	Primary	Approved 8583	Keral Approved Use Unknown
Musculoskeletal pain 10 Sources: https://clinicaltrials.gov/ct2/show/NCT03122314	Primary	Approved 8583	Keral Approved Use Unknown
Pain 619 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2c99853-1268-4998-a44b-2bf0c0b70fd2	Primary	Approved 8583	KETOPROFEN Approved Use Ketoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea. Launch Date 1992
Primary dysmenorrhea 16 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2c99853-1268-4998-a44b-2bf0c0b70fd2	Primary	Approved 8583	KETOPROFEN Approved Use Ketoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea. Launch Date 1992
Rheumatoid arthritis 320 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2c99853-1268-4998-a44b-2bf0c0b70fd2	Primary	Approved 8583	KETOPROFEN Approved Use Ketoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea. Launch Date 1992
Osteoarthritis 157 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c2c99853-1268-4998-a44b-2bf0c0b70fd2	Primary	Approved 8583	KETOPROFEN Approved Use Ketoprofen capsules USP are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen capsules USP are indicated for the management of pain. Ketoprofen capsules USP are also indicated for treatment of primary dysmenorrhea. Launch Date 1992

C_max

Value	Dose	Analyte	Population
10.1 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7439263	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	KETOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3.1 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8922555/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	DEXKETOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
3519.96 ng/mL EXPERIMENT https://www.oatext.com/pdf/TiM-19-176.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	DEXKETOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
23 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2203580/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	KETOPROFEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
6.3 mg/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2203580/	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	KETOPROFEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
21.91 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7439263	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	KETOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.03 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8922555/	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	DEXKETOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
4772.94 ng × h/mL EXPERIMENT https://www.oatext.com/pdf/TiM-19-176.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	DEXKETOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
42 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2203580/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	KETOPROFEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
74 mg × h/L REVIEW https://pubmed.ncbi.nlm.nih.gov/2203580/	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	KETOPROFEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
1.13 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/7439263	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	KETOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1.31 h EXPERIMENT https://www.oatext.com/pdf/TiM-19-176.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	DEXKETOPROFEN plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.3 h REVIEW https://pubmed.ncbi.nlm.nih.gov/2203580/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	KETOPROFEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN
8.5 h REVIEW https://pubmed.ncbi.nlm.nih.gov/2203580/	200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	KETOPROFEN plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Analyte	Population
0.8% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11368291/		DEXKETOPROFEN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
80% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1812956/		KETOPROFEN, (R)- plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6352138/	unknown, oral	KETOPROFEN plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
12.5 mg single, oral Dose: 12.5 mg Route: oral Route: single Dose: 12.5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022470s000medr.pdf	unhealthy, 36.8 years (range: 18 - 65 years) Health Status: unhealthy Age Group: 36.8 years (range: 18 - 65 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022470s000medr.pdf	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (mild, 1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022470s000medr.pdf
2400 mg single, oral Overdose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019816s011lbl.pdf	unhealthy, 45 years Health Status: unhealthy Age Group: 45 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019816s011lbl.pdf	Other AEs: Epigastric pain... Other AEs: Epigastric pain (mild, 1 patient) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019816s011lbl.pdf
100 mg 1 times / day multiple, topical Dose: 100 mg, 1 times / day Route: topical Route: multiple Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/16078335/	unhealthy, adult Health Status: unhealthy Age Group: adult Sources: https://pubmed.ncbi.nlm.nih.gov/16078335/	Sources: https://pubmed.ncbi.nlm.nih.gov/16078335/
100 ug 3 times / day steady, oral Dose: 100 ug, 3 times / day Route: oral Route: steady Dose: 100 ug, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02257970	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02257970	Other AEs: Cellulitis... Other AEs: Cellulitis (below serious, 3 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT02257970
75 ug 3 times / day steady, oral Dose: 75 ug, 3 times / day Route: oral Route: steady Dose: 75 ug, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02257970	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02257970	Other AEs: Cellulitis... Other AEs: Cellulitis (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02257970
75 ug 3 times / day steady, oral Dose: 75 ug, 3 times / day Route: oral Route: steady Dose: 75 ug, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02257970	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02257970	Other AEs: Rash... Other AEs: Rash (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT02257970
50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	Disc. AE: Headache, Hot flushes... Other AEs: Abdominal pain, Constipation... AEs leading to discontinuation/dose reduction: Headache (4.9%) Hot flushes (0.5%) Vomiting (0.5%) Stomach ache (0.5%) Other AEs: Abdominal pain (3.3%) Constipation (0.5%) Diarrhoea (2.2%) Dry mouth (0.5%) Dyspepsia (2.2%) Nausea (2.2%) Pruritus (0.5%) Rash (0.5%) Skin discoloration (0.5%) Hyperhidrosis (3.8%) Asthenia (2.2%) Rigors (1.6%) Injection site pain (9.8%) Dizziness (1.1%) Somnolence (3.3%) Neurosis (0.5%) Back pain (0.5%) Anorexia (0.5%) Vasodilatation (0.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 activator 150	inhibitor 2438	inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OAT1 725 OAT2 153 OAT3 747 OAT4 150 MRP2 499 MRP4 290 CYP1A2 2153 CYP2A6 879 UGT1A4 98 CYP2C19 2057 CYP2E1 1060 UGT1A1 246 UGT1A3 89 UGT1A9 148 UGT1A6 136 UGT2B7 197	CYP 303 UGT1A1 479 UGT1A3 470 UGT1A9 423 UGT2B4 278 UGT2B7 456

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc1NDM1In19	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc1NDM1In19	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc1NDM1In19	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc1NDM1In19	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNzU0MzUifX0=	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDc1NDM1In19	no [IC50 >10 uM]
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNzU0MzUifX0=	no [IC50 >10 uM]
UGT1A1 303	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25522350/	no [IC50 >200 uM]
UGT1A3 99	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25522350/	no [IC50 >200 uM]
UGT1A4 100	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25522350/	no [IC50 >200 uM]
UGT1A6 171	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25522350/	no [IC50 >200 uM]
UGT1A9 155	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25522350/	no [IC50 >200 uM]
UGT2B7 210	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/25522350/	no [IC50 >200 uM]
CYP3A4 2633	activator 342 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/667550#section=Biological-Test-Results	no
OAT1 730	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/10991954/	yes [IC50 1.3 uM]
MRP2 625	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17005917/	yes [IC50 1.4 uM]
MRP4 345	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/17005917/	yes [IC50 11.9 uM]
OAT2 155	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12388633/	yes [IC50 400 uM]
OAT3 749	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12388633/	yes [IC50 5.98 uM]
OAT4 150	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/12388633/	yes [IC50 70.3 uM]

Drug as victim

Target	Modality	Activity
CYP 303	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/19422321/ Page: 2.0	minor
UGT2B4 278	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15843492/ Page: 8.0	no
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15843492/ Page: 8.0	yes
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15843492/ Page: 8.0	yes
UGT1A9 423	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15843492/ Page: 8.0	yes
UGT2B4 278	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/35563116/ \| https://pubmed.ncbi.nlm.nih.gov/15843492/	yes
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15843492/ Page: 8.0	yes
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/35563116/ \| https://pubmed.ncbi.nlm.nih.gov/15843492/	yes

PubMed

Title	Date	PubMed
Iatrogenic cost factors incorporating mild and moderate adverse events in the economic comparison of aceclofenac and other NSAIDs.	2001	11548913
Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease.	2001	11511027
Use of continuous fluid drainage for severe polyhydramnios due to twin to twin transfusion syndrome.	2001	11491373
[Two complex suicidal poisonings with drugs and their medicolegal aspects].	2001	11450365
Early-morning administration of dexketoprofen-trometamol in morning stiffness induced by nodal osteoarthritis of the hands.	2001	11447775
Clinical pharmacokinetics of dexketoprofen.	2001	11368291
Overdose of ketoprofen could be dangerous.	2001 Apr	11573649
Interaction between the antinociceptive effect of ketoprofen and adrenergic modulatory systems.	2001 Aug	11580099
Simultaneous optimization based on artificial neural networks in ketoprofen hydrogel formula containing O-ethyl-3-butylcyclohexanol as percutaneous absorption enhancer.	2001 Aug	11536204
Binding constant determination of drugs toward subdomain IIIA of human serum albumin by near-infrared dye-displacement capillary electrophoresis.	2001 Aug	11519955
Investigation of the utility of an in vitro release test for optimizing semisolid dosage forms.	2001 Aug	11485188
Sustained release ketoprofen microparticles with ethylcellulose and carboxymethylethylcellulose.	2001 Aug 10	11489315
Oral ketoprofen in children--could it have been done differently?	2001 Jan	11575403
[Enantiomeric separation of drugs based on macrocyclic antibiotics].	2001 Jul	11475888
Stereoselective pharmacokinetics of ketoprofen in llamas following intravenous administration.	2001 Jun	11442802
Enantiospecific pharmacokinetics of ketoprofen in plasma and synovial fluid of horses with acute synovitis.	2001 Jun	11442795
Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery.	2001 Jun	11400845
Simultaneous photocontact sensitivity to ketoprofen and oxybenzone.	2001 Jun	11380553
Simultaneous determination of loxoprofen and its diastereomeric alcohol metabolites in human plasma and urine by a simple HPLC-UV detection method.	2001 Jun	11377045
Selective inhibition of interleukin-8-induced neutrophil chemotaxis by ketoprofen isomers.	2001 Jun 1	11331079
Intercalation compounds of hydrotalcite-like anionic clays with antiinflammatory agents--I. Intercalation and in vitro release of ibuprofen.	2001 Jun 4	11376964
Preparation and evaluation of ketoprofen floating oral delivery system.	2001 Jun 4	11376963
[Acute pancreatitis and ketoprofen].	2001 Jun-Jul	11673744
[Ketoprofen-induced acute hepatitis].	2001 Jun-Jul	11673741
I.v. ketoprofen for analgesia after tonsillectomy: comparison of pre- and post-operative administration.	2001 Mar	11573528
[Addition of clonidine to 0.5% lidocaine for intravenous locoregional anesthesia].	2001 Mar	11332061
[Allergies to ketoprofen gels].	2001 Mar 31	11317922
Thoracoscopy as a nonpharmacotherapeutic research modification for limiting postoperative chest pain.	2001 Mar-Apr	11396618
Effect of oxidative stress on the structure and function of human serum albumin.	2001 May	11465418
Chiral resolution of flurbiprofen and ketoprofen enantiomers by HPLC on a glycopeptide-type column chiral stationary phase.	2001 May	11391680
Effect of ketoprofen on muscle function and sEMG activity after eccentric exercise.	2001 May	11323536
Inhibition of synovial plasma extravasation by preemptive administration of an antiinflammatory irrigation solution in the rat knee.	2001 May	11323366
Lead-cadmium interaction effect on the responsiveness of rat mesenteric vessels to norepinephrine and angiotensin II.	2001 May 21	11369112
An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen.	2001 May 21	11337168
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.	2001 May-Jun	11386636
Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen 1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain.	2001 Nov	11697757
Measurement of ketoprofen in horse urine using gas chromatography-mass spectrometry.	2001 Oct	11696081
Influence of betacyclodextrin on the release of poorly soluble drugs from inert and hydrophilic heterogeneous polymeric matrices.	2001 Oct	11519784
Lipopolysaccharide-induced increase of prostaglandin E(2) is mediated by inducible nitric oxide synthase activation of the constitutive cyclooxygenase and induction of membrane-associated prostaglandin E synthase.	2001 Oct 1	11564815
Effects of diclofenac and ketoprofen on nerve conduction velocity in experimental nerve root compression.	2001 Oct 15	11598507
Optimized conditions of bio-mimetic artificial membrane permeation assay.	2001 Oct 9	11576780
Transdermal delivery of ketoprofen using microemulsions.	2001 Oct 9	11576778
[ Ambulatory laparoscopic gynecological surgery in Africa: feasibility].	2001 Sep	11598560
Efficacy and safety of ketoprofen lysine salt mouthwash versus benzydamine hydrochloride mouthwash in acute pharyngeal inflammation: a randomized, single-blind study.	2001 Sep	11589263
Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin.	2001 Sep	11566459
Promoting mechanism of menthol derivative, 1-O-ethyl-3-buthylcyclohexanol, on the percutaneous absorption of ketoprofen.	2001 Sep	11558566
Incompatibility of prochlorperizine and ketoprofen.	2001 Sep	11550690
Photocontact dermatitis to ketoprofen.	2001 Sep	11526526
Antihyperalgesic effects of the muscarinic receptor ligand vedaclidine in models involving central sensitization in rats.	2001 Sep	11514081
Enhancement of the activity of doxorubicin by inhibition of glutamate transporter.	2001 Sep 15	11641044

Patents

Sample Use Guides

In Vivo Use Guide

Rheumatoid Arthritis and Osteoarthritis: 75 mg three times or 50 mg four times a day. The recommended maximum daily dose of ketoprofen capsules is 300 mg/day. Pain and Dysmenorrhea: 25 to 50 mg every 6 to 8 hours as necessary.

Route of Administration: Oral

In Vitro Use Guide

5 mM Ketoprofen (mouse isolated epidermal cells)

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:42:33 GMT 2025` Edited by `admin` on `Mon Mar 31 18:42:33 GMT 2025`
Record UNII	90Y4QC304K
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

KETOPROFEN

Official Name

English

ACTRON

Preferred Name

English

R.P. 19,583

Code

English

(RS)-KETOPROFEN

Common Name

English

RU-4733

Code

English

KETOPROFEN [MART.]

Common Name

English

ISO-K

Brand Name

English

KETOPROFEN [VANDF]

Common Name

English

R.P. 19583

Code

English

SECTOR

Brand Name

English

ORUVAIL

Brand Name

English

ALRHEUMAT

Brand Name

English

RP-19583

Code

English

ketoprofen [INN]

Common Name

English

BENZENEACETIC ACID, 3-BENZOYL-.ALPHA.-METHYL-

Systematic Name

English

ORUDIS

Brand Name

English

KETOPROFEN [USP MONOGRAPH]

Common Name

English

(±)-M-BENZOYLHYDRATROPIC ACID

Systematic Name

English

IDEA-033

Code

English

NSC-758144

Code

English

(±)-KETOPROFEN

Common Name

English

ANEOL

Brand Name

English

HYDRATROPIC ACID, M-BENZOYL-

Common Name

English

KETOPROFEN [JAN]

Common Name

English

(±)-3-BENZOYL-.ALPHA.-METHYLBENZENEACETIC ACID

Systematic Name

English

KETORIN

Brand Name

English

KETOPROFEN [GREEN BOOK]

Common Name

English

KETOPROFEN [MI]

Common Name

English

KETOPROFEN [EP IMPURITY]

Common Name

English

KETOPROFEN [USAN]

Common Name

English

CAPISTEN

Brand Name

English

KETOPROFEN [ORANGE BOOK]

Common Name

English

Ketoprofen [WHO-DD]

Common Name

English

NEXCEDE

Brand Name

English

KETOPROFEN [EP MONOGRAPH]

Common Name

English

19583RP

Code

English

KETOPROFEN [USP IMPURITY]

Common Name

English

ACTRON KETOPROFEN

Brand Name

English

Classification Tree Code System Code

WHO-ATC

M01AE03

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

WHO-VATC

QM01AE53

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

WHO-VATC

QM01AE03

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

NDF-RT

N0000175722

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

LIVERTOX

NBK548678

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

NDF-RT

N0000175721

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

WHO-ATC

M02AA10

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

NCI_THESAURUS

C257

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

NDF-RT

N0000000160

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

WHO-VATC

QM02AA10

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

CFR

21 CFR 522.1225

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

WHO-ATC

M01AE53

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

Code System Code Type Description

CHEBI

6128

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

INN

3284

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

WIKIPEDIA

KETOPROFEN

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

PRIMARY

PUBCHEM

3825

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

FDA UNII

90Y4QC304K

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

SMS_ID

100000091768

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

CAS

172964-50-0

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

SUPERSEDED

EVMPD

SUB08374MIG

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

MERCK INDEX

m6622

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

Merck Index

LACTMED

Ketoprofen

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

DRUG CENTRAL

1528

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

CAS

22161-86-0

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

SUPERSEDED

NSC

758144

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

NCI_THESAURUS

C47578

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

DAILYMED

90Y4QC304K

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

ChEMBL

CHEMBL571

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

ECHA (EC/EINECS)

244-759-8

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

RXCUI

6142

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

RxNorm

CAS

22071-15-4

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

PRIMARY

CAS

154907-35-4

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

SUPERSEDED

DRUG BANK

DB01009

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

MESH

D007660

Created by admin on Mon Mar 31 18:42:33 GMT 2025 , Edited by admin on Mon Mar 31 18:42:33 GMT 2025

PRIMARY

RS_ITEM_NUM

1356632

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

EPA CompTox

DTXSID6020771

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

IUPHAR

4795

Created by admin on Mon Mar 31 18:42:34 GMT 2025 , Edited by admin on Mon Mar 31 18:42:34 GMT 2025

PRIMARY

Related Record Type Details


					4HZ67LW8L7

OAT-4

TRANSPORTER -> INHIBITOR


					S03709D0TH

KETOPROFEN, (R)-

ENANTIOMER -> RACEMATE


					I81U7H57XI

OAT-1

TRANSPORTER -> INHIBITOR


					6KD9E78X68

DEXKETOPROFEN

ENANTIOMER -> RACEMATE


					5R10M39KS7

KETOPROFEN SODIUM

SALT/SOLVATE -> PARENT


					ZWJ2Y6JZWY

OAT-3

TRANSPORTER -> INHIBITOR


					90Y4QC304K

KETOPROFEN

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (TITRATION)

Qualification:

EP

Amount:


					029SOQ8920

KETOPROFEN ARGININE

SALT/SOLVATE -> PARENT


					5840721PJZ

OAT-2

TRANSPORTER -> INHIBITOR


					6D53G0FD0Z

PLASMA PROTEIN FRACTION (HUMAN)

BINDER->LIGAND

Interaction Type:

BINDING

Amount:


					90Y4QC304K

KETOPROFEN

BASIS OF STRENGTH->SUBSTANCE

Interaction Type:

ASSAY (TITRATION)

Qualification:

USP

Amount:

Related Record Type Details


					J7V17Q435V

3-(CYANOMETHYL)BENZOIC ACID

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					T1XT2245YV

2-(3-BENZOYLPHENYL)PROPIONITRILE

IMPURITY -> PARENT


					2TIQ8I948E

2-(3-(2,4,5-TRIMETHYLBENZOYL)PHENYL)PROPANOIC ACID, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					3DQM4A09S7

3-ACETYLBENZOPHENONE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					3PN2M0G40N

3-(1-CYANOETHYL)BENZOIC ACID

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					50IY2AXR5Q

KETOPROFEN AMIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					V4267UCZ9S

2-(3-(4-METHYLBENZOYL)PHENYL)PROPANOIC ACID

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					57OG4Q7B6Y

(3-BENZOYLPHENYL)ACETIC ACID

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					U76LP2N35E

3-(1-CARBOXYETHYL)BENZOIC ACID, (±)-

IMPURITY -> PARENT


					3DQM4A09S7

3-ACETYLBENZOPHENONE

IMPURITY -> PARENT


					V4267UCZ9S

2-(3-(4-METHYLBENZOYL)PHENYL)PROPANOIC ACID

IMPURITY -> PARENT


					B6ZW00N616

2-(3-(2(5),3,4-TRIMETHYLBENZOYL)PHENYL)PROPANOIC ACID, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					779OZE6Y5X

2-(3-(2,4-DIMETHYLBENZOYL)PHENYL)PROPANOIC ACID, (±)-

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					Y444TA4HYW

(3-BENZOYLPHENYL)ETHANENITRILE

IMPURITY -> PARENT

Comments:

UNSPECIFIED

Qualification:

EP


					UPX6W85296

3-BENZOYLBENZOIC ACID

IMPURITY -> PARENT


					U76LP2N35E

3-(1-CARBOXYETHYL)BENZOIC ACID, (±)-

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:


					S65R4656M1

METHYL-2-(3-BENZOYLPHENYL)PROPANOATE, (S)-

IMPURITY -> PARENT


					T1XT2245YV

2-(3-BENZOYLPHENYL)PROPIONITRILE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

EP

Amount:

Related Record Type Details


					90Y4QC304K

KETOPROFEN

ACTIVE MOIETY

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Volume of Distribution	PHARMACOKINETIC

Biological Half-life	PHARMACOKINETIC

AE	Significance	Dose	Population
Rash	mild, 1 patient Disc. AE	12.5 mg single, oral Dose: 12.5 mg Route: oral Route: single Dose: 12.5 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022470s000medr.pdf	unhealthy, 36.8 years (range: 18 - 65 years) Health Status: unhealthy Age Group: 36.8 years (range: 18 - 65 years) Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022470s000medr.pdf
Epigastric pain	mild, 1 patient	2400 mg single, oral Overdose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019816s011lbl.pdf	unhealthy, 45 years Health Status: unhealthy Age Group: 45 years Sex: F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/019816s011lbl.pdf
Cellulitis	below serious, 3 patients	100 ug 3 times / day steady, oral Dose: 100 ug, 3 times / day Route: oral Route: steady Dose: 100 ug, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02257970	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02257970
Cellulitis	below serious, 1 patient	75 ug 3 times / day steady, oral Dose: 75 ug, 3 times / day Route: oral Route: steady Dose: 75 ug, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02257970	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02257970
Rash	below serious, 1 patient	75 ug 3 times / day steady, oral Dose: 75 ug, 3 times / day Route: oral Route: steady Dose: 75 ug, 3 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02257970	unhealthy Health Status: unhealthy Sources: https://clinicaltrials.gov/ct2/show/NCT02257970
Anorexia	0.5%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Back pain	0.5%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Constipation	0.5%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Dry mouth	0.5%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Neurosis	0.5%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Pruritus	0.5%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Rash	0.5%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Skin discoloration	0.5%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Vasodilatation	0.5%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Hot flushes	0.5% Disc. AE	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Stomach ache	0.5% Disc. AE	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Vomiting	0.5% Disc. AE	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Dizziness	1.1%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Rigors	1.6%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Asthenia	2.2%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Diarrhoea	2.2%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Dyspepsia	2.2%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Nausea	2.2%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Abdominal pain	3.3%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Somnolence	3.3%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Hyperhidrosis	3.8%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Headache	4.9% Disc. AE	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/
Injection site pain	9.8%	50 mg 2 times / day multiple, intramuscular Highest studied dose Dose: 50 mg, 2 times / day Route: intramuscular Route: multiple Dose: 50 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/17638394/

Details

SMILES

InChI

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

PubMed

Patents

Sample Use Guides

C_max

T_1/2

F_unbound

Drug as perpetrator